Skip to main content

Market Overview

Aslan Pharmaceuticals Shares Are Trading Higher On Positive ASLAN004 Data In Atopic Dermatitis

Share:

Aslan Pharmaceuticals Ltd (NASDAQ: ASLN) announces positive interim unblinded data from its ongoing Phase 1 study evaluating ASLAN004 to treat moderate to severe atopic dermatitis (AD).

  • Subcutaneous delivery of ASLAN004 was shown to be well tolerated across all doses (200mg, 400mg, and 600mg) and showed improvements compared to placebo in all efficacy endpoints.
  • At week 8, the average reduction in eczema severity index from baseline at therapeutic doses (400mg and 600mg cohorts) was 74% compared to 42% on placebo.
  • A 50% decrease in eczema index was observed in 89% ASLAN004 treated patients than 40% on placebo.
  • A 75% and 90% decrease in eczema index was seen in 67% and 56% of the patients in ASLAN004, respectively, compared to none on placebo.
  • The proportion of patients with adverse events and treatment-related adverse events were similar across treatment and placebo arms.
  • Full unblinded data from approximately 50 patients are expected in mid-2021.
  • The company plans to initiate a global Phase 2b study later this year.
  • ASLAN's management will host a webcast and conference call at 8 am ET today.
  • Price Action: ASLN shares jumped 78.3% at $7.92 in premarket trading on the last check Monday.
 

Related Articles (ASLN)

View Comments and Join the Discussion!

Posted-In: atopic dermatitisBiotech News Penny Stocks Contracts FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com